StockNews.com initiated coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Free Report) in a research report report published on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Agile Therapeutics Price Performance
Shares of NASDAQ:AGRX opened at $1.51 on Friday. The firm has a fifty day moving average price of $1.48 and a two-hundred day moving average price of $0.91. The company has a market cap of $10.35 million, a price-to-earnings ratio of -0.41 and a beta of 1.58. Agile Therapeutics has a one year low of $0.20 and a one year high of $2.63.
Agile Therapeutics (NASDAQ:AGRX – Get Free Report) last posted its earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter. The company had revenue of $5.58 million during the quarter.
Institutional Investors Weigh In On Agile Therapeutics
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
See Also
- Five stocks we like better than Agile Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Canada Bond Market Holiday: How to Invest and Trade
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- NYSE Stocks Give Investors a Variety of Quality Options
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.